1,2,3,4-Tetrahydronaphthalene-1-sulfonamide | 1247756-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1,2,3,4-Tetrahydronaphthalene-1-sulfonamide
• CAS: 1247756-17-7
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.28
• InChiKey: SRYALXBZLHTHHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] CCR8 INHIBITORS<br/>[FR] INHIBITEURS DU CCR8
  申请人：MILLENNIUM PHARM INC

  公开号：WO2004058709A1

  公开（公告）日：2004-07-15

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I). The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  揭示了由结构式（I）代表的CCR8抑制剂。结构式（I）中的变量在此处描述。还揭示了通过向受试者施用所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。
• SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS
  申请人：Boehm Marcus F.

  公开号：US20150299179A1

  公开（公告）日：2015-10-22

  Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

  提供了选择性调节鞘氨醇1磷酸受体的化合物，包括调节S1P受体亚型1的化合物。还提供了此类化合物的手性合成方法。与治疗或预防疾病、不良状况和紊乱相关的用途、治疗方法或预防方法以及制备包括创新化合物的创新组合物的方法被提供，其中调节鞘氨醇1磷酸受体在医学上是适用的。
• [EN] SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE ET PROCÉDÉS DE SYNTHÈSE CHIRALE
  申请人：RECEPTOS INC

  公开号：WO2011060389A1

  公开（公告）日：2011-05-19

  Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the SlP receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

  提供了选择性调节鞘氨醇1磷酸受体的化合物，包括调节SlP受体亚型1的化合物。提供了这类化合物的手性合成方法。与调节鞘氨醇1磷酸受体相关的治疗或预防方法，以及制备包括这些创新化合物的创新组合物的方法，用于治疗或预防需要医学干预的疾病、异常情况和疾病。
• [EN] TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DÉRIVÉS DE SULFONAMIDE DE TÉTRALINE POUR L'UTILISATION DANS LE TRAITEMENT DE TROUBLES DE PROLIFÉRATION
  申请人：UNIV NOTRE DAME DE LA PAIX

  公开号：WO2012175654A1

  公开（公告）日：2012-12-27

  Tetraline sulfonamides derivatives highly specific towards CA IX and/or CA XII human carbonic anhydrase for targeting solid tumors.

  四环磺胺衍生物对人类碳酸酐酶CA IX和/或CA XII具有高度特异性，用于靶向固体肿瘤。
• CCR8 Inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040209948A1

  公开（公告）日：2004-10-21

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I): 1 The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  本发明涉及由结构式（I）表示的CCR8抑制剂：1结构式（I）中的变量在此文中进行了描述。本发明还涉及通过向受试者给予所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。